Myasthenia Gravis Exacerbation Following BRAF and MEK Inhibitor Therapy

Authors

DOI:

https://doi.org/10.17161/rrnmf.v4i2.18636

Keywords:

myasthenia gravis, melanoma, vemurafenib, cobimetinib

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

References

Alabdali M, Bril V, Morgan E, Pereira A, Maurice C. An Unprecedented Case of Myasthenia Gravis Induced by Binimetinib. J Clin Case Rep 2019; 9:1291.

Zaloum A, Falet JPR, Elkrief A, & Chalk C. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma. Neurology, 2020; 94(7), 322-323.

Ziogas DC, Mandellos D, Theocharopoulos C, Lialios PP, Bouros S, Ascierto PA, & Gogas H. Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. Frontiers in Oncology, 2021; 11, 727010.

Woman standing at a window holding a scale

Downloads

Published

2023-06-19

Issue

Vol. 4 No. 2 (2023)

Section

Clinic and Case Reports

License

Copyright (c) 2023 Jeremy Hill MD, Yuebing Li MD PhD

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Hill, J., & Li, Y. (2023). Myasthenia Gravis Exacerbation Following BRAF and MEK Inhibitor Therapy. RRNMF Neuromuscular Journal, 4(2), 16-17. https://doi.org/10.17161/rrnmf.v4i2.18636